Transaction DateRecipientSharesTypePriceValue
29th May 2020Tina Gullotta6,000Open or private purchase$0.33$1,989.00
2nd December 2019Capital Iv, Lp Aisling689,655Grant/award etc.$1.45$999,999.75
29th November 2019William P. Quinn6,000Open or private purchase$0.37$2,193.00
15th July 2019Capital Iv, Lp Aisling2,500,000Open or private purchase$0.60$1,500,000.00
31st May 2019William P. Quinn6,000Open or private purchase$0.65$3,876.60
11th April 2019Capital Iv, Lp Aisling428,571Grant/award etc.$3.50$1,499,998.50
28th February 2019William P. Quinn63,697Grant/award etc.$0.00
Sunesis Pharmaceuticals
Sunesis Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.


Ticker: SNSS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1061027
Employees: 24
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals